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Since the pioneering discovery of the rapid CNS depressant actions of steroids by the
“father of stress,” Hans Seyle 70 years ago, brain-derived “neurosteroids” have emerged
as powerful endogenous modulators of neuronal excitability. The majority of the interven-
ing research has focused on a class of naturally occurring steroids that are metabolites of
progesterone and deoxycorticosterone, which act in a non-genomic manner to selectively
augment signals mediated by the main inhibitory receptor in the CNS, the GABAA receptor.
Abnormal levels of such neurosteroids associate with a variety of neurological and psychi-
atric disorders, suggesting that they serve important physiological and pathophysiological
roles. A compelling case can be made to implicate neurosteroids in stress-related distur-
bances. Here we will critically appraise how brain-derived neurosteroids may impact on
the stress response to acute and chronic challenges, both pre- and postnatally through
to adulthood. The pathological implications of such actions in the development of psy-
chiatric disturbances will be discussed, with an emphasis on the therapeutic potential of
neurosteroids for the treatment of stress-associated disorders.
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INTRODUCTION
In the 1940s, the Hungarian endocrinologist, Dr. Hans Selye
demonstrated that certainpregnane steroids could induce sedation
and anesthesia on a relatively rapid time scale, a property which
precludes a genomic action (Selye, 1941). The molecular mech-
anism underlying the rapid depressant action of these pregnane
steroids remained unknown until the early 1980s, when Harrison
and Simmonds (1984) demonstrated that a structurally related
synthetic steroidal anesthetic, alphaxalone (5α-pregnane-3α-ol-
11,20-dione), potently enhanced GABAA receptor (GABAAR)
function (a receptor for the main inhibitory neurotransmitter in
the CNS) in a brain slice preparation. Subsequent studies revealed
that certain endogenously synthesized steroids, such as the prog-
esterone (PROG) metabolites 5α-pregnan-3α-ol-20-one (5α3α-
THPROG), 5β-pregnan-3α-ol-20-one (5β3α-THPROG), and the
deoxycorticosterone (DOC) metabolite 5α-pregnan-3α,21-diol-
20-one (5α3α-THDOC),were similarly potent (10–100 nM) posi-
tive allostericmodulators of GABAAR function (Barker et al., 1987;
Callachan et al., 1987; Gee et al., 1987, 1988; Harrison et al., 1987;
Lambert et al., 1987, 2009; Peters et al., 1988). Indeed, the observed
enhancement of GABAAR function by such steroidswas consistent
with their behavioral actions (anxiolytic, anticonvulsant, sedative,
analgesic, and anesthetic; Lambert et al., 1995; Gasior et al., 1999;
Rupprecht, 2003). The subsequent demonstration that brain lev-
els of neurosteroids occur within a range known to be active at
the GABAAR led to the proposal that they may act as endogenous
regulators of GABAAR function (reviewed in Lambert et al., 1995).
GABAA receptors are responsible for mediating the major-
ity of fast inhibitory neurotransmission within the CNS and
are the target of a number of clinically signiﬁcant compounds,
including benzodiazepines (BDZ) such as diazepam and a variety
of structurally diverse general anesthetics and anticonvulsants,
including propofol, etomidate, and members of the barbiturate
class, e.g., thiopentone (Olsen and Sieghart, 2009). This recep-
tor class possesses a pentameric structure, surrounding a central
anion conducting pore. To date, 19 subunits have been identiﬁed
(α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3), that are divided into subfam-
ilies based upon their amino acid homology (Olsen and Sieghart,
2008, 2009). These subunits exhibit distinct expression proﬁles
and allow for the expression of ∼20–30 different GABAAR iso-
forms within the mammalian CNS (Fritschy and Brunig, 2003;
Olsen and Sieghart, 2008). The subunit composition regulates
the pharmacological and biophysical properties of the GABAAR
(Olsen and Sieghart, 2009), in addition to inﬂuencing the regional
expression and cellular location (e.g., synaptic or extrasynaptic).
GABAAR isoforms incorporating the γ2 subunit, in combination
with α and β subunits are ubiquitously expressed throughout the
brain (Wisden et al., 1992; Fritschy and Brunig, 2003) and are pre-
dominantly, but not exclusively, located within the synapse, where
they are responsible for mediating “phasic” GABAergic inhibition
(Farrant and Nusser, 2005). In contrast, δ-containing GABAARs
(δ-GABAARs) display a more discrete expression proﬁle, being
primarily prevalent in the cerebellum, dentate gyrus, thalamus,
striatum, and cortex (Wisden et al., 1992; Fritschy and Mohler,
1995) where they are expressed only at peri- and extrasynaptic
locations (Nusser et al., 1998; Wei et al., 2003) and mediate a
“tonic” form of GABAergic inhibition (Farrant and Nusser, 2005).
The apparent sensitivity of native GABAARs to neurosteroid
modulation is inﬂuenced by a variety of factors including the sub-
unit composition of the receptor, phosphorylation reactions, and
local metabolism (Belelli and Lambert, 2005). As an example of
the ﬁrst, evidence from recombinant expression systems indicates
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that δ-GABAARs are signiﬁcantly more sensitive to modulation by
endogenous neurosteroids, than their γ2-containing counterparts
(Belelli et al., 2002; Brown et al., 2002). However, the preferen-
tial interaction with δ-GABAARs is secondary to GABA acting as
a partial agonist at this receptor subtype, thus allowing for the
magnitude of the steroid response to be signiﬁcantly greater than
for the homologous γ2-containing receptors (Bianchi and Mac-
donald, 2003). Consequently, neurosteroidmodulation of extrasy-
naptic δ-GABAARs has received considerable attention and these
receptors have been proposed to play an important role in medi-
ating the physiological effects of these compounds (Maguire and
Mody, 2009). However, it should be noted that endogenous neu-
rosteroids display neuron-speciﬁc actions uponGABAAR function
and that certain synaptic (γ2-containing) GABAARs are similarly
sensitive to physiological neurosteroid concentrations in speciﬁc
brain regions (Cooper et al., 1999; Herd et al., 2007; Belelli et al.,
2009).
Recent site-directed mutagenesis studies have revealed that the
activation and potentiation of GABAARs by endogenous neu-
rosteroids are mediated by two discrete groups of amino acid
residues, housed in the GABAAR transmembrane domains (Hosie
et al., 2006). Thus, αT236 and βY284 regulate neurosteroid (i.e.,
5α3α-THPROG and 5α3α-THDOC)-induced GABAAR activa-
tion, whilst αQ241 and αN407 are implicated in the GABA-
modulatory effects of these steroids (Hosie et al., 2006). How-
ever, subsequent studies have suggested the neurosteroid bind-
ing pocket to have a more complex structure with additional
residues, e.g., α1S240 contributing to the modulatory actions of
steroid molecules of different structure (Akk et al., 2008). Of
relevance to the interaction of neurosteroids with δ-GABAARs,
GABA-evoked currents mediated by recombinant α4β3δ recep-
tors in which the critical glutamine residue of the α4 subunit was
mutated (α4Q246L) are insensitive to 5α3α-THDOC. This obser-
vation suggests that the δ subunit does not contribute directly
to the GABA-modulatory neurosteroid binding site (Hosie et al.,
2009).
It has been postulated that the differential accumulation of
neurosteroids within the lipid membrane (due to their lipophilic-
ity) serves to increase their local concentration, and as such, these
steroids may diffuse laterally, through the membrane, to access low
afﬁnity binding site(s) on GABAARs, a proposal consistent with
a putative transmembrane docking site (Akk et al., 2005; Chisari
et al., 2010).
Within the brain, the levels of endogenous steroids derived
from either central, or peripheral sources, are sufﬁcient to mod-
ulate GABAAR function (Paul and Purdy, 1992; Corpéchot et al.,
1993; Mellon and Vaudry, 2001; Mellon and Grifﬁn, 2002). Initial
studies suggested that steroid synthesizing enzymes were primar-
ily expressed in glia (Melcangi et al., 1993). However, it is now
apparent that the enzymes necessary for steroidogenesis are also
expressed in certain neurons (Tsutsui, 2008; Do Rego et al., 2009)
Therefore, as originally postulated, neurosteroids may function as
endocrine messengers, but could additionally act in a paracrine, or
indeed autocrine manner as local neuromodulators to “ﬁne tune”
inhibitory transmission (Agis-Balboa et al., 2006). Interestingly,
the endogenous levels of neurosteroids within the CNS are not
static, but are dynamically regulated in response to a number of
physiological states, including development, stress, puberty, preg-
nancy, and during the ovarian cycle (Purdy et al., 1991; Paul
and Purdy, 1992; Maguire and Mody, 2009; Shen et al., 2010).
A number of psychological conditions, including panic attacks,
major depression, postpartum depression, premenstrual tension,
and schizophrenia, have been associated with perturbations in the
levels of neurosteroids within the CNS (Purdy et al., 1991; Eser
et al., 2006; Smith et al., 2006; Uzunova et al., 2006; Longone
et al., 2008), while treatment with certain psychoactive drugs (e.g.,
ethanol, ﬂuoxetine) can perturb the levels of these neurosteroids
(Uzunova et al., 1998; Sundstrom-Poromaa, 2004; Biggio et al.,
2007).
This review will focus on the impact of endogenous neuros-
teroids upon inhibitory transmission within the CNS in both
physiological and pathophysiological scenarios, with an empha-
sis on their documented and potential role within the stress
neurocircuitry.
THE INFLUENCE OF “LOCAL” NEUROSTEROIDS ON
NEURONAL INHIBITION: PHYSIOLOGICAL RELEVANCE
As noted above and discussed further below, several lines of evi-
dence are consistent with the proposal that GABAAR-mediated
inhibition may be subject to ﬁne tuning by locally produced
steroids. Although a signiﬁcant proportion of these neurosteroids
are derived from peripheral sources including the adrenal cortex
and the ovaries (Paul and Purdy, 1992), the brain is a steroido-
genic organ, capable of de novo synthesis of these neuromod-
ulators (Purdy et al., 1991; Mellon, 2004; Agis-Balboa et al.,
2006; Do Rego et al., 2009). Thus, the enzymes and mitochon-
drial transporters necessary for the synthesis of GABAAR-active
pregnane steroids are expressed in the CNS. The synthesis of
5α3α-THPROGand5α3α-THDOC fromPROGandDOCrespec-
tively, requires two sequential reactions catalyzed by 5α-reductase
and 3α-hydroxysteroid dehydrogenase (3α-HSD; Karavolas and
Hodges, 1990; Figure 1). These key enzymes are expressed within
the CNS in a region-speciﬁc manner and often, are co-localized
(Agis-Balboa et al., 2006). Furthermore, the expression of these
enzymes is not limited to GABAergic neurons. Thus, for example
both enzymes are selectively expressed in glutamatergic principal
neurons in the cortex and hippocampus, whilst in the cerebel-
lum and thalamus their co-expression is restricted to Purkinje and
nucleus reticularis thalami (nRT) neurons, which are GABAer-
gic (Agis-Balboa et al., 2006; Tsutsui, 2008). These observations
raise the prospect that the excitability of neurons, which co-
express GABAARs and the steroid synthesizing enzymes may be
self-regulated by the neurosteroid acting in an autocrine manner
(Agis-Balboa et al., 2006; Herd et al., 2007; Figure 2).
Recent experimental evidence lends considerable support to
the notion that locally produced neurosteroids can modulate neu-
ronal excitability. At synaptic and extrasynaptic GABAARs the
effect of these neuromodulators is typicallymanifest as a prolonga-
tion of the decay time of inhibitory postsynaptic currents (IPSCs)
and an increase in the tonic conductance respectively. The treat-
ment (5 h previously) of mice with the 5α-reductase inhibitor SKF
105111 (17β-17-[bis (1methylethyl) amino carbonyl]; Figure 1)
resulted in a reduction in the decay time of spontaneous IPSCs
(sIPSCs) recorded from cortical neurons, suggesting the presence
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FIGURE 1 | A model for the regulation of neurosteroidogenesis. A
diagrammatic representation of the pathways for the biosynthesis of
5α3α-THPROG from cholesterol. Receptors and signaling mechanisms
potentially regulating steroidogenesis and sites of action of ligands used to
target selective enzymatic pathways are additionally illustrated. In the
proposed model, NMDA receptor activation may stimulate
neurosteroidogenesis on a rapid time scale (Tokuda et al., 2011), possibly via
the Ca2+ induced activation of nNOS and p38 MAPK (Izumi et al., 2008). In
addition, glucocorticoids may regulate neurosteroidogenesis via rapid
non-genomic effects through the activation of Gs-γβ, an effect that stimulates
nNOS (Di et al., 2009). Furthermore, a number of stress-related neuropeptides
(e.g., CRH, AVP), which are known to signal through Gs-coupled receptor
complexes may modulate nNOS activity and thus inﬂuence neurosteroid
synthesis. Receptors for these neuropeptides can additionally couple to
Gq-proteins to raise intracellular Ca2+ levels and thus, couple to signaling
cascades similar to those associated with NMDA receptor activation. These
GPCR-dependent signaling pathways may provide a functional regulatory link
between the stress axis and the de novo synthesis of 5α3α-THPROG.
of an endogenous neurosteroid tone in these cells (Puia et al.,
2003). In the hippocampus, CA1 pyramidal neurons are sensitive
to physiologically signiﬁcant concentrations of 5α3α-THPROG
(100 nM), while the same concentration of the neurosteroid has
no effect upon inhibitory transmission in dentate gyrus gran-
ule cells (DGGCs). However, the metabolically stable synthetic
analog, ganaxolone, enhances inhibitory transmission at low con-
centrations in CA1 neurons and DGGCs (Belelli and Herd, 2003).
Interestingly, 3α-HSD, unlike 5α-reductase, is involved in both
the synthesis and degradation of 5α3α-THPROG (and 5α3α-
THDOC) as the cytosolic isoform catalyzes the reductive forma-
tion of 5α3α-THPROG from 5α-dihydroprogesterone (5α-DHP),
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FIGURE 2 | A model for neurosteroid actions at the GABAA receptor
within the stress neurocircuitry. (A) A diagrammatic representation of the
HPA axis. The release of CRH from the dorsal–medial parvocellular neurons
(mpd) of the PVN is regulated by humoral negative feedback pathways and
neuronal inputs from higher brain structures (e.g., the limbic system and the
forebrain regions). Inputs from the forebrain and the limbic structures do not
directly innervate the PVN, but form polysynaptic connections via a number
of predominantly GABAergic “relay nuclei” (red) surrounding the PVN, such
as the BST mPOA, DH, and peri-PVN (Cullinan et al., 2008). In the proposed
model stress-induced endogenous neurosteroids derived from peripheral
sources (e.g., 5α3α-THDOC) and or synthesized de novo within the CNS
(e.g., 5α3α-THPROG) may act to enhance the GABAergic inhibition in the
PVN and surrounding neurons. Additionally, neurosteroids may modulate
inhibitory transmission within limbic and forebrain regions to inﬂuence their
neuronal output and hence HPA activity. (B) Physiological concentrations of
5α3α-THPROG (100 nM) dramatically reduce the frequency of action
currents recorded fromWT mpd neurons in a hypothalamic slice preparation
containing the PVN and surrounding structures, thus inhibiting their output
(i.e., CRH release). Local excitatory inputs (e.g., glutamatergic, green),
which are themselves constrained by inhibitory GABAegic neuron (red)
originating in the BST and local hypothalamic nuclei (Herman et al., 2002)
drive the release of neuropeptides from mpd neuron (gray) of the PVN. (C) A
diagrammatic representation of a representative PVN synapse (either
GABAergic or glutamatergic). Neurosteroids (e.g., 5α3α-THPROG)
synthesized following a stressful challenge, may act both at presynaptic or
postsynaptic locations in an autocrine or paracrine fashion respectively to
enhance GABAAR inhibition. Note that at presynaptic terminals due to the
intraneuronal Cl− gradient, GABA may be depolarizing (Trigo et al., 2008) and
thus neurosteroids may act to increase neurotransmitter release. Note that
although extrasynaptic δ-GABAA receptors are absent in the PVN, other
γ2-GABAARs may be expressed extrasynaptically at GABAergic or
glutamatergic synapses.
whilst the membrane-bound isoform promotes the reverse, oxida-
tive reaction (Li et al., 1997). In DGGCs the membrane-bound
3α-HSD isoform is predominant,and the inhibitionof this enzyme
with indometacin, or the contraceptive agent Provera (Figure 1),
results in amodest prolongation of miniature IPSCs (mIPSCs) and
an enhancement of the endogenous tonic conductance of DGGCs
(Belelli and Herd, 2003). Collectively, these observations are con-
sistent with the proposal that local metabolism may play a crucial
role in shaping GABAAR-mediated inhibition in a neuron-speciﬁc
fashion.
The translocator protein 18 kDa [TSPO; formerly the
mitochondrial benzodiazepine receptor (MBR) or peripheral
benzodiazepine receptor (PBR); Figure 1; Papadopoulos et al.,
2006; Batarseh and Papadopoulos, 2010], is located on the
outer mitochondrial membrane where it functions together with
the steroidogenic acute regulator protein (StAR; Sierra, 2004;
Figure 1) to transport cholesterol into mitochondria, a prereq-
uisite and the rate-limiting step for steroid and neurosteroid
synthesis (Rupprecht et al., 2010). The anxiolytic drug etifox-
ine, in addition to allosterically enhancing GABAAR function,
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activates TSPO to increase the cerebral production of 5α3α-
THPROG, an effect that contributes to the behavioral actions
of the drug (Verleye et al., 2005). Moreover, the selective TSPO
activator, XBD173 (N -benzyl-N -ethyl-2-[7,8-dihydro-7-methyl-
8-oxo-2-phenyl-9H -purin-9-yl] acetamide; Figure 1) enhances
the amplitude and duration of evoked IPSCs (eIPSCs) and mIP-
SCs recorded from neurons of the mouse medial prefrontal cortex
(mPFC), an effect blocked by the 5α-reductase inhibitor, ﬁnas-
teride (Rupprecht et al., 2009). Crucially, XBD173 is effective in
tests predictive of an anxiolytic action [i.e., social isolation and ele-
vated plus-maze (EPM) tests], with both actions being blocked by
the TSPO antagonist PK11195 [1-(2-chlorophenylmethylpropyl)-
3-isoquinoline-carboxamide; Figure 1; Rupprecht et al., 2009].
Importantly, in humans XBD173 acts as an effective anxiolytic
agent, without the sedative, or the withdrawal symptoms typi-
cally associated with current therapeutic treatments for anxiety
(Rupprecht et al., 2009).
Certain benzodiazepines (BDZs), such as diazepam and mida-
zolam not only act to enhance GABAAR function, but also to
promote the synthesis of neurosteroids through the activation of
TSPO (Rupprecht et al., 2010; Tokuda et al., 2010; Figure 1). For
example, in a brain slice preparation, midazolam, a BDZ used
clinically to facilitate the induction of anesthesia, increased neu-
rosteroid levels in CA1 pyramidal neurons and inhibited LTP
(Tokuda et al., 2010). Consistent with a neurosteroid involve-
ment, inhibiting neurosteroid synthesis with ﬁnasteride treatment,
or inhibiting the GABA-modulatory actions of neurosteroids
with the selective antagonist 17PA [17-phenyl-(3α5α)-androst-
16-en-3-ol; Mennerick et al., 2004] signiﬁcantly attenuated the
actions of midazolam (Tokuda et al., 2010). Furthermore, in vivo
ﬁnasteride pre-treatment blocked the inhibitory effects of mida-
zolam upon contextual fear learning (Tokuda et al., 2010). In
contrast, clonazepam, an anxiolytic, and anticonvulsant BDZ,
does not induce changes to neurosteroid synthesis and has no
effect upon LTP induction. However, when administered with
the TSPO agonist FGIN (2-[2-(4-ﬂuorophenyl)-1H -indol-3-yl),
or together with exogenous allopregnanolone, clonazepam pro-
duced similar effects to midazolam, thus inhibiting LTP induction
(Tokuda et al., 2010). These observations suggest that the unique
effects of certain clinically important BDZs may be mediated
by the dual activation of TSPO and potentiation of GABAAR
function.
PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL ROLE OF
NEUROSTEROIDS: A FOCUS ON STRESS
INHIBITORY REGULATION OF THE STRESS CIRCUITRY
The ability of an organism to adapt to conditions of stress is
essential for survival and involves a number of ﬁnely regulated
and highly conserved interconnected systems that maintain phys-
iological homeostasis. The hypothalamic paraventricular nucleus
(PVN) is a key brain region involved in initiating the neuroen-
docrine and autonomic response to stressor exposure (Herman
and Cullinan, 1997). Within the PVN, spinally projecting parvo-
cellular neurons (located in dorsal and ventromedial parvocel-
lular regions), rapidly modulate autonomic output in response
to stress exposure, while neuroendocrine parvocellular neurons
(located in the dorsomedial parvocellular region), project to the
median eminence and initiate activation of the hypothalamo-
pituitary–adrenocortical (HPA) axis (Ulrich-Lai and Herman,
2009). Regulation of the HPA axis is mediated through the inte-
gration of hormonal feedback pathways, e.g., glucocorticoids,
corticotrophin-releasing hormone (CRH), and a complex neuro-
circuitry involving a number of mono- and polysynaptic pathways
(Herman et al., 2003; de Kloet et al., 2005; Ulrich-Lai and Her-
man, 2009; Figure 2A). The PVN receives considerable GABAergic
innervation from local hypothalamic regions (e.g., dorsal hypo-
thalamus, peri-PVN, preoptic area) and areas of the extended
amygdala (e.g., bed nucleus of the stria terminalis, BST), that exert
a substantial inhibitory tone upon the HPA axis (Cullinan et al.,
2008). Forebrain and limbic regions (e.g., hippocampus, amyg-
dala, and prefrontal cortex) do not directly innervate the PVN, but
insteadmodulateHPAactivity via projections to a number of these
GABAergic nuclei surrounding the PVN (Ulrich-Lai and Herman,
2009; Figure 2A). As such, these “relay nuclei” are important sites
of stress integration, located “upstream” of the PVN and it is con-
ceivable that the modulation of inhibitory transmission at this
level by neurosteroids, may play a role in this synaptic integration
(Figure 2A).
Quantitative ultrastructural analysis has revealed that CRH-
releasing parvocellular neurons are the main target for GABAergic
inputs to the medial parvocellular region of the PVN (Miklos
and Kovacs, 2002). Furthermore, dual in situ hybridization stud-
ies have demonstrated the mRNA expression of multiple GABAAR
subunits (α1, α2, β1–3, and γ1, γ2) in the majority of CRH-
releasing neurons (Cullinan, 2000), providing molecular evidence
for a role of GABAAR-mediated inhibition at the level of the
HPA axis. In agreement with this anatomical data, electrophys-
iological recordings from acute hypothalamic slice preparations
revealed that glutamate microinjection into regions surrounding
the PVN elicited postsynaptic potentials sensitive to the GABAAR
antagonist bicuculline in a signiﬁcant proportion of parvocellular
neurons (Boudaba et al., 1996), while bicuculline also increased
the frequency of action currents in these neurons (Hewitt et al.,
2009). Furthermore, the microinjection of bicuculline into the
PVN in vivo resulted in increased plasma corticosterone levels
(Cullinan et al., 2008; Hewitt et al., 2009), whilst in contrast,
microinjection of the GABAAR agonist muscimol reduced the cir-
culating levels of this steroid (Cullinan et al., 2008). Collectively,
these observations suggest that GABAAR-mediated inhibition is
important for the regulation of HPA axis activity. Given this
prominent role for GABA within the local stress neurocircuitry,
it is conceivable that the rapid elevation of neurosteroid lev-
els that occurs during stress (Purdy et al., 1991), may act as a
brake upon HPA axis activity by enhancing the GABAergic inhi-
bition exerted upon the PVN (Figure 2A). Indeed, the steroid
synthesizing enzymes 5α-reductase and 3α-HSD are expressed
and 5α3α-THPROG immunoreactivity can be detected within the
hypothalamus and extended amygdala respectively (Li et al., 1997;
Eechaute et al.,1999;Gao et al.,2002; Saalmannet al.,2007). There-
fore, locally produced neurosteroids could potentially contribute
to the control of HPA activity.
The following section will discuss the physiological and patho-
physiological roles of endogenous neurosteroids in acute and
chronic stress.
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ACUTE STRESS
Early behavioral studies demonstrated the anxiolytic properties
of pregnane steroids in a variety of animal models of anxiety
(Crawley et al., 1986; Bitran et al., 1995; Carboni et al., 1996).
In addition, the levels of 5α3α-THPROG and 5α3α-THDOC were
rapidly elevated in the rodent hypothalamus and cortex following
exposure to an acute swim stress (Purdy et al., 1991). Interestingly,
adrenalectomy prevented the stress-induced increase in brain lev-
els of 5α3α-THDOC, but not 5α3α-THPROG demonstrating the
de novo synthesis of the latter neurosteroid in response to stress
(Purdy et al., 1991). Similarly, elevated levels of 5α3α-THDOC,
following exposure to an acute swim stress, raised the thresh-
old of pentylenetetrazol (PTZ)-induced seizures in a ﬁnasteride-
and indometacin-sensitive manner (Reddy and Rogawski, 2002).
Collectively, these observations suggest that neurosteroids synthe-
sized de novo within the CNS together with those derived from
peripheral sources (i.e., 5α3α-THDOC from the adrenal cortex;
Eser et al., 2005) may play a physiological role in modulating the
stress response.
In electrophysiological recordings made from neonatal mouse
[postnatal (PN) days 18–24] hypothalamus, we ﬁnd low concen-
trations (10–100 nM) of 5α3α-THPROG to enhance the synaptic
inhibition of neuroendocrine parvocellular neurons of the PVN
and to inhibit their output (Belelli et al., 2009; Figure 2B). In com-
mon, the output of spinally projecting parvocellular neurons is
similarly reduced by low concentrations of 5α3α-THDOC (Wom-
ack et al., 2006).Neuroendocrine parvocellular neurons are known
to activate the HPA axis through the release of CRH (Vale et al.,
1981) and i.c.v. injection of this neuropeptide induces behaviors
closely resembling those associatedwith stress and anxiety (Owens
and Nemeroff, 1991). Interestingly, the anxiogenic effects of CRH
in rats exposed to the EPM were inhibited in a dose-dependent
manner by pre-treatment with 5α3α-THPROG (Patchev et al.,
1994). Additionally, although having no effect upon basal CRH
release in vitro, 5α3α-THPROG did suppress the methoxamine
[an α1-adrenoreceptor (α1-AR) agonist]-induced release of this
neuropeptide (Patchev et al., 1994). This in vitro observation is
intriguing given that the parvocellular region of the PVN receives
considerable noradrenergic inputs from the nucleus of the soli-
tary tract and the locus coeruleus (Cunningham and Sawchenko,
1988). Both of these structures are believed to trigger responses
to “physical” stressors, an effect that is possibly mediated via a
contribution by α1-ARs (Daftary et al., 2000; Han et al., 2002).
Themagnitude andpolarity of GABAAR-mediated neurotrans-
mission is critically dependent upon the transmembrane Cl−
gradient. Thus, generally, an increase in the intracellular Cl− con-
centration can shift the GABA-mediated response from neuronal
hyperpolarization (inhibitory) to depolarization (excitatory). The
transmembrane Cl− gradient is maintained by cation-chloride
co-transporters (CCC), with Na+–K+–2Cl− co-transporter 1
(NKCC1) and K+–Cl− transporter 2 (KCC2) being responsible
for the majority of neuronal Cl− uptake and extrusion respec-
tively within the CNS. Crucially the relative functional expression
of these transporters appears not to be static, but dynamically reg-
ulated during certain physiological (e.g., development) and patho-
physiological states (reviewed in Blaesse et al., 2009). Interestingly,
a recent study has suggested that exposure to acute restraint
stress functionally down-regulates KCC2 such that the action
of GABA in neuroendocrine parvocellular neurons shifts from
being hyperpolarizing to depolarizing, thus profoundly weaken-
ing synaptic inhibitory transmission (Hewitt et al., 2009). The
authors postulate that activation of α1-ARs underlies the depo-
larizing shift in the reversal potential for GABA (EGABA), most
likely via the activation of protein kinase C (PKC). The ability
of secondary messenger systems to indirectly and dynamically
modulate the inhibitory tone exerted upon the HPA axis through
changes in KCC2 function may be an important mechanism in
the initiation and termination of the physiological response trig-
gered by stress. Intriguingly, GABAergic transmission (measured
by [35S] t -butylbicyclophosphorothionate (TBPS) binding and
36Cl− uptake), has long been known to be rapidly (within 5min)
decreased following various forms of acute stress (Sanna et al.,
1992; Barbaccia et al., 1996; reviewed in Biggio et al., 2007),
whereas the subsequent increases in brain and plasma neuros-
teroid levels peaked 30min after the onset of stress and was
correlated with the restoration of GABAergic transmission and
reduced anxiety-like behavior (Barbaccia et al., 2001). These ﬁnd-
ings support the proposal that the neuroendocrine and autonomic
responses to a stressor may be modulated by these endogenous
neurosteroids, which in this scenario would act to terminate the
stress response.Nevertheless, although as noted above the enzymes
are expressed within this region (Eechaute et al., 1999), it remains
to be determined whether these neurosteroids are actually pro-
duced de novo, speciﬁcally in the PVN and nearby surrounding
regions in response to a stressful challenge.
DOC mediates many of the physiological responses to acute
stress (Reddy, 2006). Thus, it is conceivable that metabolites of
this steroid, e.g., 5α3α-THDOC may contribute to other stress-
induced alterations in inhibitory transmission via their actions on
the GABAAR (Reddy, 2006). Indeed, the exposure of mice to a sin-
gle acute hypoxic challenge increases expression of the GABAAR δ
subunit in the hippocampus and enhances the GABAAR-mediated
tonic conductance of DGGCs (Maguire and Mody, 2007). The
incubation of brain slices for 30min with 5α3α-THDOC followed
by a 30- to 120-min washout period of the steroid, induced a
similar increase in the tonic conductance of DGGCs (Maguire
and Mody, 2007). The mechanism(s) responsible for this 5α3α-
THDOC-induced up-regulation of δ-GABAARs remain to be
determined. However, the previously reported “glucocorticoid-
like” effects of endogenous neurosteroids (Patchev et al., 1994,
1996) and the GABAAR-dependent modulation of neuropeptide
expression (Cole and Sawchenko, 2002; Bali and Kovacs, 2003;
Brunton et al., 2009) within the PVN may be relevant in this
respect.
CHRONIC STRESS
Exposure to chronic or repeated stress induces signiﬁcant struc-
tural and functional alterations within the stress neurocircuitry,
which are primarily and initially involved in promoting adap-
tation by allostasis, but in the long term can have deleterious
effects upon brain function (Joels et al., 2007; McEwen, 2010).
Indeed, dysregulation of the HPA axis has been implicated in
the pathogenesis of a number of psychiatric and neurological
conditions including depression, post-traumatic stress disorder
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(PTSD), and Alzheimer’s (Holsboer, 2000; Schule et al., 2009).
Furthermore, the levels of endogenous neurosteroids in plasma
and cerebrospinal ﬂuid (CSF) are altered in patients suffering from
various stress-related affective disorders (Uzunova et al., 2006).
Neurosteroids, chronic stress, and brain plasticity
Chronic stress exposure results in a number of functional and
molecular adaptations including altered dendritic morphology
in stress-related brain regions such as the mPFC (Radley et al.,
2005, 2008; Liston et al., 2006; Goldwater et al., 2009), hip-
pocampus (Woolley et al., 1990; Magarinos and McEwen, 1995),
and amygdala (Mitra and Sapolsky, 2008). These alterations in
dendritic morphology are accompanied by behavioral changes,
including impaired cognitive function (Bodnoff et al., 1995),
increased anxiety (Mitra and Sapolsky, 2008), and abnormal atten-
tional set-shifting (Liston et al., 2006). Interestingly, the observed
stress-induced dendritic remodeling appears to be reversible, pro-
vided animals receive appropriate recovery time following stress
exposure (Radley et al., 2005; Goldwater et al., 2009). Chronic
stress-inducedmorphological alterations appear to bemediated by
both sex and stress hormones (e.g., estrogen, glucocorticoids) and
are accompanied by changes in synapse formation and receptor
expression (Joels et al., 2007; McEwen, 2010). Thus, the behav-
ioral deﬁcits associated with chronic stress may be a consequence
of network disruption in corticolimbic areas, an effect that may
be contributed by, and secondary to, the remodeling of dendritic
architecture within these brain structures (Goldwater et al., 2009).
Relatively little is known regarding the inﬂuence that endoge-
nous neurosteroids have upon the morphological alterations asso-
ciated with chronic stress and major depression. However, the
regenerative potential of 5α3α-THPROG has been explored in
animal models of Alzheimer’s disease, the pathogenesis of which
has recently implicated chronic stress as a signiﬁcant contribut-
ing factor (Sotiropoulos et al., 2011). The proliferative effects of
neurosteroids have been demonstrated in vitro using cerebellar
granule cells (Keller et al., 2004), rat hippocampal, and human
cortical neural progenitor cells (Wang et al., 2005), raising the
possibility that the regenerative potential of neurosteroids may be
therapeutically beneﬁcial (Wang et al., 2008). In a mouse model of
Alzheimer’s disease (3xTgAD),male adult (3months old) 3xTgAD
mice displayed signiﬁcant reductions in cell proliferation in the
hippocampal subgranular zone (SGZ) and behaviorally exhibited
deﬁcits in a hippocampal associative learning and memory task,
i.e., trace eye blinking conditioning (Wang et al., 2010). Intrigu-
ingly, in the 3xTgADmouse, 5α3α-THPROG, in a dose-dependent
manner, signiﬁcantly increased cell proliferation in the SGZ to
levels found in corresponding wild type mice, whilst also revers-
ing the cognitive deﬁcits (Wang et al., 2010). Indeed, the survival
of early progenitor cells in the 3xTgAD mouse correlated with
the enhanced memory performance produced by 5α3α-THPROG
treatment, suggesting that early neurogenic deﬁcitsmay contribute
to the cognitive phenotype associated with Alzheimer’s disease.
Therefore, such neurosteroids may potentially serve as a regenera-
tive therapeutic, to alter the development and progression of such
neurodegenerative diseases (Wang et al., 2010). Indeed, a recent
study has revealed that 5α3α-THPROG restored neural progen-
itor cell survival and associative learning and memory in adult
male 3xTgAD mice that only exhibit intraneuronal amyloid β (Aβ;
i.e., ≤9months old). By contrast, the neurosteroid was ineffec-
tive in later stages of the disease (at the age of 12months) when
extraneuronal Aβ plaques become apparent (Singh et al., 2011).
Collectively, these ﬁndings indicate that the therapeutic efﬁcacy of
this neurosteroid is dependent upon the stage of AD pathology.
Intriguingly, there appears to be many similarities between the
endocrine (e.g., hypersecretion of glucocorticoids) and neuronal
(e.g., dendritic remodeling) modiﬁcations reported in the patho-
genesis of both Alzheimer’s and depression (Lupien et al., 2009).
Thus, it is tempting to speculate that the regenerative potential of
5α3α-THPROG observed by Wang et al. (2010) in a mouse model
of Alzheimer’s disease may also reduce the depressive-like behav-
iors and cognitive deﬁcits associated with prolonged chronic stress
exposure. The ability of neurosteroids to increase cell proliferation
and to restore corticolimbic network function may contribute to
the putative antidepressant actions of certain steroids (Uzunova
et al., 1998). Of interest, in patients suffering from Alzheimer’s
disease the levels of the endogenous neurosteroid 5α3α-THPROG
are reduced throughout the brain, but particularly in stress-related
brain structures such as the hippocampus, amygdala, hypothala-
mus, and frontal cortex (Weill-Engerer et al., 2002). Furthermore,
although CRH induced an increase in plasma 5α3α-THPROG in
patients suffering from Alzheimer’s disease, the neurosteroid lev-
els remained signiﬁcantly lower than in control patients (Bernardi
et al., 2000). Therefore, it is conceivable that neurosteroids may
be less effective in mediating the physiological responses to stress
in patients suffering from this disease and restoration of normal
levels may prove therapeutically beneﬁcial.
Chronic stress exposure not only induces remodeling of den-
dritic architecture, but additionally alters synapse formation and
the expression of various neurotransmitter receptors (Joels et al.,
2007; McEwen, 2010). Given that endogenous neurosteroids, such
as 5α3α-THPROG and 5α3α-THDOC, are such potent positive
allosteric modulators of GABAAR function, and that GABAARs
have such a prominent inﬂuence on the HPA axis, the impact that
chronic stress has upon GABAAR-mediated inhibition within the
brain is of particular interest. The majority of research has focused
upon chronic stress-induced alterations in the excitatory neuro-
transmitter systems, with relatively little attention being given
to the GABAergic system. However, the expression of mRNAs
encoding for certain GABAAR subunits was altered in the rat
hippocampus following the chronic exposure to levels of corti-
costerone achieved during stress (Orchinik et al., 1995), although
the functional signiﬁcance of this altered expression remains unex-
plored.The impact that stress has uponbrain function (e.g.,LTP) is
dependent upon the level of glucocorticoid elevation and the dura-
tion of the stressor exposure, in addition to the brain region under
consideration (Lupien et al., 2009). Nevertheless, in chronically
stressed rats, hippocampal LTP is difﬁcult to evoke (Alfarez et al.,
2003) and this scenario can be mimicked in control non-stressed
animals by the activation of glucocorticoid receptors (GRs), i.e.,
following20minpre-incubationof hippocampal slices in corticos-
terone (100 nM;Alfarez et al., 2002).Whether this effect of chronic
stress is associated with an altered expression of GABAARs as
recently described for the hippocampus and mPFC of Alzheimer’s
patients (Rissman et al., 2007; Luchetti et al., 2011), is not known.
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At the level of the PVN, chronic variable stress signiﬁcantly
increases the number of glutamatergic and noradrenergic termi-
nals apposing CRH-immunopositive cell bodies and dendrites,
whilst having no effect upon the number of GABAergic termi-
nals (Flak et al., 2009). Thus, the balance between excitatory and
inhibitory control of the HPA axis appears signiﬁcantly altered fol-
lowing chronic stress exposure. Although the number of GABAer-
gic terminals apposing parvocellular neurons was unchanged, a
marked down-regulation of the β1 and β3 GABAAR subunits
was observed following chronic variable stress (Cullinan and
Wolfe, 2000). This effect may indirectly modulate the neuros-
teroid sensitivity of these receptors (Fancsik et al., 2000; Brussaard
and Koksma, 2003; Harney et al., 2003) via documented kinase-
speciﬁc interactions with β subunit isoforms (Kittler and Moss,
2003). Electrophysiological recordings from parvocellular neu-
rons derived from rats exposed to chronic variable stress revealed
a reduction in the frequency of mIPSCs, supporting the notion
of reduced GABAergic inhibition of these neurons (Verkuyl et al.,
2004). However, in contrast to themorphological data, a reduction
in the mIPSC frequency with no change to the paired pulse ratio
would suggest a reduction in the number of GABAergic synapses
apposing these neurons (Verkuyl et al., 2004). Clearly, the impact
that these alterations in GABAAR expression in stress–sensitive
brain structures have upon neurosteroid modulation of the stress
response deserves further investigation.
A number of preclinical and clinical studies have implicated
5α3α-THPROGandother 3α-reducedneurosteroids indepression
and attributed the anxiolytic properties of some antidepressants
of the selective serotonin reuptake inhibitors (SSRI) class (e.g.,
ﬂuoxetine or Prozac®) to these endogenous neuromodulators
(Guidotti and Costa, 1998; Eser et al., 2006; Uzunova et al., 2006).
In support, the brain levels of 5α3α-THPROG are signiﬁcantly
decreased in animal models of depression or PTSD (Serra et al.,
2000, 2008; Pinna, 2010) and similarly the levels of this neuros-
teroid are also reduced in the plasma andCSF of depressed patients
(Romeo et al., 1998; Uzunova et al., 1998). In addition, treatment
with exogenous neurosteroids produces robust antidepressant-like
actions in rodent models of depression (Pinna et al., 2009), while
in humans elevated 5α3α-THPROG levels have been associated
with a reduction in depressive behavior (reviewed in Uzunova
et al., 2006). Intriguingly, animal studies have revealed that acute
treatment with the SSRI ﬂuoxetine normalizes the brain levels of
5α3α-THPROG in a stereospeciﬁc manner (Uzunov et al., 1996;
Matsumoto et al., 1999; Serra et al., 2001; Pinna et al., 2004;
Figure 1). Similarly, the CSF levels of this neurosteroid are also
restored in depressed patients following SSRI treatment (Romeo
et al., 1998; Uzunova et al., 1998). The ﬂuoxetine-induced increase
in neurosteroid levels occurs at concentrations signiﬁcantly lower
than those required to block serotonin reuptake and on a faster
time scale (i.e., ∼30min) than that associated with the clinical
improvement by classical antidepressants (i.e., 3 weeks; Uzunov
et al., 1996;Guidotti andCosta,1998;Pinna et al., 2004). Therefore,
enhancement of GABAAR-mediated inhibition may contribute to
the anxiolytic actions of this SSRI (Longone et al., 2008). Fluoxe-
tine has been postulated to increase the levels of 5α3α-THPROG
by either potentiating the reduction of 5α-DHP, or by inhibiting
the oxidation of 5α3α-THPROG back to 5α-DHP, possibly via the
modulation of 3α-HSD activity (Uzunov et al., 1996). In support,
Grifﬁn andMellon (1999) reported that ﬂuoxetine andother SSRIs
(e.g., paroxetine) enhanced the reductive function of recombinant
rat and human forms of 3α-HSD. However, a direct interaction of
SSRIs with 3α-HSD remains controversial as a subsequent study
did not support these ﬁndings (Trauger et al., 2002).
Plasma and CSF levels of neurosteroids measured in clinical
studies may not accurately reﬂect their brain levels, particularly if
such steroids are acting in a paracrine or autocrine manner. Con-
sequently, determining whether alterations in neurosteroid levels
following SSRI treatment reduce depressive behaviors has proved
difﬁcult. However, a number of non-pharmacological antidepres-
sant treatments, including electroconvulsive therapy (ECT) and
repetitive transcranial magnetic stimulation (rTMS), all failed to
alter the levels of 5α3α-THPROG, although they produced clin-
ical improvement of patients suffering from major depression
(Padberg et al., 2002; Baghai et al., 2005). Moreover, although
partial sleep deprivation (PSD) ameliorated symptoms in 60% of
patients suffering from major depression, the concentrations of
neurosteroids were not affected by PSD in either responders or
non-responders (Schule et al., 2003). Similarly, responders and
non-responders to treatment with the antidepressant mirtazapine
exhibited similar neurosteroids levels (Schule et al., 2006). Collec-
tively, although a dysregulation of neurosteroid equilibrium has
been consistently reported in animalmodels and in humans suffer-
ing fromdepression, it remains unclear whether the normalization
of neurosteroid levels following ﬂuoxetine treatment is actively
involved in alleviating depressive symptoms, or is simply a phar-
macological by-product associated with clinical improvement, i.e.,
changes in neurosteroid production may reﬂect distinct proper-
ties of certain antidepressants rather then alleviation of mood
symptoms (Uzunova et al., 2006).
PROGRAMMING OF THE STRESS RESPONSE: A ROLE FOR
NEUROSTEROIDS?
The maturation of the HPA axis is highly sensitive to prena-
tal and postnatal stress, resulting in adverse alterations in the
behavioral and neuroendocrine responses to stress in adulthood.
In the accompanying section we will consider speciﬁcally the
role of neurosteroids in animal models of prenatal and postna-
tal stress and their potential relevance to the etiology of stress-
associated pathologies, e.g., depression, Alzheimer’s disease, and
drug addiction.
PRENATAL STRESS
Exposure of the fetal brain to stress, or glucocorticoids, can inﬂu-
ence the development of physiological systems resulting in an
increased susceptibility in adulthood to cardiovascular (Barker,
2002), metabolic (Levitt et al., 2000), and affective disorders (Wel-
berg and Seckl, 2001). Indeed, the exposure of pregnant rats
(gestation day 14, G14) to chronic restraint stress resulted in off-
spring that displayed an anxious-like phenotype both as neonates
(P7) and adults. Intriguingly, these behavioral effects of prenatal
stress (PNS) were attenuated by the concomitant administration
of 5α3α-THPROG to the pregnant dams (G14; Zimmerberg and
Blaskey, 1998). Similarly, Brunton and Russell have explored a
putative role for neurosteroids in a model of social PNS (social
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defeat of a female rat during the last week of pregnancy by
a resident lactating rat). In this model, both male and female
adult offspring displayed exaggerated adrenocorticotropic hor-
mone (ACTH) and corticosterone responses to an acute stress
challenge, i.e., interleukin-1β (IL-1β) administration (Brunton
andRussell, 2010). Interestingly,prior treatment (2 and 20 hbefore
the IL-1β challenge)with 5α3α-THPROGnormalized the exagger-
ated (approximately threefold) ACTH response in female, but not
male adult rats exposed prenatally (i.e., during the last week of
pregnancy) to social PNS (Brunton and Russell, 2011). However,
the testosterone metabolite androstanediol, which also enhances
GABAAR function (Gee et al., 1988; Reddy and Jian, 2010), nor-
malized the HPA response to IL-1β of male PNS rats (Brunton
and Russell, 2011). These observations are consistent with the
proposal that neurosteroidogenesis may be compromised in the
adult brain of rats exposed to PNS. Yet, the mechanism whereby
these neurosteroids restore the neuroendocrine response to IL-1β
administration is currently unclear, although given the prominent
role of GABAAR-mediated inhibition in the stress neurocircuitry
(Cullinan et al., 2008), potentiation of GABAAR function is likely
to contribute. For example, neurosteroid administration to PNS
adult rats may restore HPA sensitivity through a mechanism sim-
ilar to that previously described in dams during the ﬁnal stage
of pregnancy (Brunton et al., 2009). Thus, during late pregnancy
(pregnancy day 21), the maternal response to an IL-1β challenge
is reduced due to the inhibition of noradrenergic inputs to the
PVN. This effect appears consequent to an increased expression
of enkephalin and presynaptic μ-opioid receptors, an adaptation
that is critically dependent on 5α3α-THPROG (Brunton et al.,
2009). An attractive possibility worthy of investigation is that neu-
rosteroids such as 5α3α-THPROGand androstanediolmay induce
similar adaptations in adult PNS rats to normalize the endocrine
response to IL-1β administration (see Brunton and Russell, 2011).
While the speciﬁc mechanism whereby 5α3α-THPROG induces
increased enkephalin and opioid receptor expression in pregnant
rats remains to be elucidated, the “glucocorticoid-like” effects
of neurosteroids upon CRH and vasopressin (AVP) expression
within the PVN (Patchev et al., 1994, 1996) and the modulation of
PVNneuropeptide expression byGABAARs (Cole and Sawchenko,
2002; Bali and Kovacs, 2003) warrant further investigation. Of fur-
ther note, the fetal neuroprotective actions of 5α3α-THPROGmay
not be exclusively associated with direct effects within the fetal
brain, as elevated maternal levels of this neurosteroid during the
latter stages of pregnancy act to reduce the sensitivity of maternal
HPA axis to stressful challenges, and hence, the exposure of the
fetus to maternally derived glucocorticoids (reviewed in Brunton
and Russell, 2008).
Perturbations in neurosteroid levels have also been reported in
the fetal brain following an acute hypoxic challenge induced by
constriction of the umbilical cord, a response, which may result
from increased 5α-reductase and cytochrome P450scc expression
within the brain (Nguyen et al., 2004). The observed elevation
in central neurosteroid levels in response to hypoxia may repre-
sent an endogenous neuroprotective mechanism in the develop-
ing brain. In agreement, binding studies, using [35S] TBPS have
revealed that by late gestation GABAARs are signiﬁcantly more
sensitive to 5α3α-THPROG modulation than in the adult brain
(Crossley et al., 2000). In contrast, exposure to chronic hypoxic
stress (induced through the injection of inert microspheres into
the fetal circulation) increased the expression of the neurosteroid
synthesizing enzyme 5α-reductase in most brain regions, but had
no effect upon the amount of 5α3α-THPROG in the fetal brain
after 20 days of hypoxemia (Nguyen et al., 2003). The reduced
capacity of the fetus to synthesize 5α3α-THPROG in response to a
chronic hypoxic challenge may result from a reduction in the sup-
ply of maternally derived 5α3α-THPROG and/or the impaired
metabolism of progesterone to other neurosteroid precursors.
However, the ability of the fetal brain to synthesize other neu-
roactive steroids and the impact that acute and chronic stress
have upon this remains unknown. Collectively, these observations
suggest that neurosteroids such as 5α3α-THPROG may be impor-
tant neuroprotective agents within the fetal brain (reviewed in
Hirst et al., 2009). In this context, it is conceivable that the doc-
umented excitatory and trophic actions of GABA in the prenatal
CNS (Represa and Ben-Ari, 2005) are not incidental to the neuro-
protective actions of neurosteroids. However, it should be noted
that the excitatory actions of GABA,observed during development
have also been associated with neuronal damage (e.g., epilepsy-see
Dzhala et al., 2005).
Few studies havemeasured changes in brain function associated
with PNS in humans. However, children of mothers who during
pregnancy experienced stress, depression, or anxiety, or who were
treated with glucocorticoids, exhibit increased basal HPA activ-
ity, thus indicating that there are long-lasting alterations affecting
the child’s normal development of the stress response (reviewed
in Lupien et al., 2009). This altered HPA programming may con-
tribute to the increased vulnerability of the progeny to affective
disorders in later life (Bale et al., 2010).
POSTNATAL STRESS
Endogenous neurosteroids have also been implicated in the post-
natal maturation of the HPA axis. The early postnatal period is
crucial in the development and maturation of the HPA axis and is
characterized in rodents, by a period (PN4–14) of marked hypore-
sponsivity (Sapolsky and Meaney, 1986). As this period coincides
with stages of axonal growth, synaptogenesis, and myelination of
key brain circuits, it has been postulated that this hyporesponsive
phenotype protects the developing brain from excessive glucocor-
ticoid exposure. Adverse early life events are known to result in
profound and long-lasting alterations in the mature organism’s
behavioral and neuroendocrine response to stress (Francis and
Meaney, 1999). Speciﬁcally, the mother–pup interaction has been
shown to strongly inﬂuence the maturation of the stress neuro-
circuitry, as both in rodents and in primates reduced maternal
care is associated with impaired behavioral and neuroendocrine
responses to stress in adulthood (Sanchez et al., 2001). Conversely,
enhanced maternal care increases the ability to cope with stressful
experiences in later life (Francis et al., 1999).
Suggesting a possible role for neurosteroids in the program-
ming of the stress response, 5α3α-THPROG reduced the number
of ultrasonic vocalizations (USVs), a measure of an anxious-like
phenotype, in neonatal (PN7) rat pups previously exposed to
maternal separation (Zimmerberg et al., 1994, 1999), while mater-
nally separated (between PN 2 and 7) neonatal rats displayed a
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reduction in the number of USVs compared to non-stressed con-
trols when exposed to a subsequent maternal separation at PN8
(Zimmerberg et al., 1999). Interestingly, the adaptation exhibited
by maternally separated pups to a subsequent separation corre-
lated with enhanced 5α3α-THPROG levels in the brain following
maternal separation (Kehoe et al., 2000). Thus, it is tempting to
speculate that neurosteroid-induced enhancement of GABAer-
gic inhibition may contribute to this hyporesponsive phenotype.
However,maternally separated rats exhibited a more anxious phe-
notype in response to a novel stressor than their non-stressed
counterparts (Patchev et al., 1997; Zimmerberg et al., 1999).More-
over, for adult rats that have been maternally separated (PN 2–10)
mRNA levels of CRHandGRmRNAwere increased and decreased
in the PVN and the hippocampus, respectively. Interestingly, these
behavioral and neuroendocrine alterations were attenuated when
5α3α-THDOC was concomitantly administered during mater-
nal separation, suggesting that these 5α-reduced neurosteroids
may exert persistent stress–protective effects during development
(Patchev et al., 1997). Intriguingly, the level of 3α-HSD mRNA has
been shown to be elevated in the dentate gyrus of male and female
rats at P7, a time coinciding with the stress hyporesponsive period,
further supporting a physiological role for endogenous neuros-
teroids at this stage of development (Mitev et al., 2003). Behavioral
and neuroendocrine dysregulation induced by neonatal mater-
nal separation exhibits differences between genders (Mitev et al.,
2003), although such effects may be additionally dependent on the
maternal separation protocol utilized (Zimmerberg and Kajun-
ski, 2004). Thus, adult male, but not female rats that experienced
maternal separation (PN 5-10) exhibited a more anxious-like phe-
notype on the EPM than their non-stressed counterparts (Mitev
et al., 2003). However, ovariectomized (OVX) female rats exposed
to maternal separation in infancy exhibited an anxious-like phe-
notype on the EPM in adulthood cf control females, suggesting
that peripheral steroids may normally mask the behavioral conse-
quences of neonatal stress in females. Moreover, the concomitant
administration of 5α3α-THPROG during maternal separation
counteracted the behavioral and neuroendocrine consequences
of neonatal stress in both genders (Mitev et al., 2003).
Supporting the notion that abnormal GABAAR function is
associated with exposure to early life adversities, early life stress
induces changes to the expression of GABAARs that occur con-
comitantly with the perturbations of behavior and neuroen-
docrine function described above. These changes in expression
are evident in brain regions that are important for the processing
of “psychogenic” stressors, a function known to be signiﬁcantly
altered in adulthood by early life stress (Caldji et al., 2003). In
general, offspring receiving good quality maternal care displayed
signiﬁcantly greater mRNA expression of α1 and β3-subunits in
limbic and forebrain regions in comparison to those that received
low quality maternal care (Caldji et al., 2003). Intriguingly, the
majority of changes observed in GABAAR subunit expression
appeared to be unique to the amygdala, a region important in
the development of fear-related memory (Ehrlich et al., 2009;
Roozendaal et al., 2009). Thus, in the central (CeA), basolat-
eral (BLA), and lateral (LA) amygdaloid nuclei, adult offspring
that had experienced high-quality maternal care expressed sig-
niﬁcantly greater mRNA levels of both γ1 and γ2-subunits, the
latter being important in mediating the majority of actions of
benzodiazepines. However, in the central and basolateral regions
of the amygdaloid nucleus, low-maternal care offspring exhibited
relatively greater levels of α3 and α4 mRNA (Caldji et al., 2003).
How these changes in the levels of subunit mRNAs translate to
perturbations of synaptic/extrasynaptic inhibition, or to changes
in the sensitivity of native GABAARs to neurosteroid modulation
provides scope for future investigations.
Changes in GABAAR subunit expression may also be asso-
ciated with altered localization of GABAergic interneurons in a
manner similar to that described by Grobin et al. (2003) for the
prefrontal cortex following elevated levels of neurosteroids dur-
ing development. Such a scenario in the amygdala, hippocampus,
and prefrontal cortex may severely compromise the ability of an
organism to process and cope with a variety of stressors. In this
regard, it would be of interest to investigate whether the quality of
maternal care inﬂuences neurosteroids levels and their actions in
the developing brain. The proposal that extrasynaptic δ-GABAARs
may mediate some of the physiological actions of neurosteroids
may be relevant in this respect (Maguire and Mody, 2009). Thus,
a recent study has indicated maternal care to be compromised
in mice lacking the δ subunit (δ0/0 mice – Maguire and Mody,
2008). Moreover, genetic inactivation of this subunit blunts the
anxiolytic actions of neurosteroids in an acute stress challenge
paradigm in adult mice (Mihalek et al., 1999). Collectively, these
ﬁndings raise the intriguing prospect that early life stress may
encode long-lasting changes in network function, contributing to
the loss of the anxiolytic action of neurosteroids in adult δ0/0 mice.
Consistentwith this suggestion, the output of neuroendocrine par-
vocellular neurons of the hypothalamic PVN is insensitive to the
inhibitory actions of the neurosteroid 5α3α-THPROG in neonatal
(PN18–P24) mice lacking the δ subunit cf wild type counterparts
(Gunn et al., 2010). However, complicating the interpretation of
these ﬁndings, δ-GABAAR are not expressed in the PVN (Wisden
et al., 1992; Gunn et al., 2010). This observation suggests that these
receptors are unlikely to be the direct molecular target of 5α3α-
THPROG within the PVN and caution should be exercised when
directly implicating δ-GABAARs in the actions of neurosteroids
based upon δ “knock out” studies.
In contrast to long periods of maternal separation, short
episodes (∼15min) induce a neuroendocrine plasticity that is
characterized by reduced stress responses (Plotsky and Meaney,
1993; Avishai-Eliner et al., 2001), enhanced resilience to depressive
behaviors (Meaney et al., 1991), and improved learning and mem-
ory function (Fenoglio et al., 2005). Augmented maternal care in
the early postnatal period (PN 2–P8), results in reduced levels of
CRH expression within the PVN during adulthood. Interestingly,
this effect was associated with a reduction in glutamatergic inner-
vation of neuroendocrine parvocellular neurons during postnatal
development and the increased expression of the transcription
repressor neuron-restrictive silencer factor (NRSF), an adapta-
tion maintained through to adulthood (Korosi et al., 2010). Thus,
the reduced glutamatergic excitation in the postnatally develop-
ing PVN may be important in initiating the reprogramming of
CRH expression, possibly via the induction of genomic and epi-
genetic modiﬁcations, which, in turn, would result in increased
stress resilience in later life (Korosi et al., 2010). Whether limbic
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and forebrain stress centers exhibit similar adaptations deserves
further investigation as alterations in the neuronal architecture
of these brain structures could signiﬁcantly amplify individual
stress vulnerability, or resilience. Moreover, epigenetic adaptations
resulting from speciﬁc mother–pup interactions have the poten-
tial to be transmitted across subsequent generations to impact on
their susceptibility to stress exposure (Weaver et al., 2004;Tsankova
et al., 2007; Murgatroyd et al., 2009; Brunton and Russell, 2011;
Curley et al., 2011).
In agreement with animal models of postnatal stress, studies
in human subjects have revealed that early stress has a signiﬁ-
cant negative impact upon brain development and function in
children, which may predispose individuals to develop affective
disorders in adulthood (reviewed in Repetti et al., 2002; McEwen,
2003). Speciﬁcally, the timing and severity of early life stress has
been postulated to induce pathophysiological alterations within
the CNS that increases the stress vulnerability of individuals, pre-
disposing them to psychiatric disorders in later life (McGowan
et al., 2009; Neigh et al., 2009). Consistent with this proposal, epi-
genetic reductions in hippocampal glucocorticoid feedback have
been associated with childhood abuse and increased risk of suicide
(McGowan et al., 2009), an effect that is analogous to alterations
in hippocampal GR expression in rats exposed to low quality of
maternal care (Weaver et al., 2004).
Whether in humans early life stress induces alterations of neu-
rosteroid levels, similar to those described for a variety of animal
models is currently not known, but if so they may be of patho-
logical relevance. Indeed, normalization of such levels may be
therapeutically beneﬁcial in a manner similar to that reported
for depressed patients (Uzunov et al., 1996). In this respect, the
recent demonstration that XBD173 stimulates the synthesis of
GABAAR-active steroids and in humans this drug acts as an effec-
tive anxiolytic, suggests that novel therapeutic strategies for the
treatment of early stress-related disturbances may be possible
(Rupprecht et al., 2009).
REGULATION OF NEUROSTEROID SYNTHESIZING ENZYMES;
A ROLE FOR GLUCOCORTICOIDS AND NEUROPEPTIDES?
Although acute stress rapidly elevates brain neurosteroid levels in
rodents (Purdy et al., 1991), the mechanism(s) by which a stressor
induces neurosteroidogenesis is currently unknown. Indeed, rel-
atively little is known regarding the mechanisms responsible for
regulating the activity of steroid synthesizing enzymes and trans-
porters such as TSPO, 5α-reductase, and 3α-HSD within the CNS.
However, a recent study indicates that NMDA receptor activation
can rapidly (within 5min) increase the levels of neurosteroids
in hippocampal CA1 neurons (Tokuda et al., 2011), possibly sig-
naling via p38 mitogen-activated protein kinase (MAPK), neu-
ronal nitric oxide synthase (nNOS), and calcineurin (Izumi et al.,
2008; Figure 1). Additionally, certain steroid hormones, e.g., cor-
ticosterone and estrogen, as well as the neuropeptide CRH, can
modulate the levels of endogenous neurosteroids in a gender and
steroid-speciﬁc manner (Torres et al., 2001; Mitev et al., 2003).
For example, Mitev et al. (2003) have reported corticosterone to
increase 3α-HSD expression in both genders. In contrast, proges-
terone, a precursor of 5α3α-THPROG had no effect upon 3α-HSD
expression in either gender, indicating that the activity of 3α-HSD
is not simply correlated with substrate levels. These observa-
tions suggest that following stress exposure, the resultant elevated
corticosterone levels may increase 3α-HSD expression and conse-
quently, increase the levels of neurosteroids probably via classical
genomic mechanisms. However, glucocorticoids can additionally
exert rapid, non-genomic effects in a number of stress-related
brain structures (Tasker and Herman, 2011), and such actions may
contribute to curtailing HPA activity (Tasker and Herman, 2011).
The molecular mechanism of rapid glucocorticoid signaling, and
the impact of this steroid hormone upon neuronal excitability
appears to be brain region, neuron, and even synapse speciﬁc (Di
et al., 2003, 2005, 2009;Karst et al., 2005, 2010; Tasker andHerman,
2011). For example, in magnocellular neurons of the supraoptic
nucleus (SON) and PVN, glucocorticoids activated divergent G-
protein signaling pathways to inhibit and increase the release of
glutamate and GABA respectively, in a synapse-speciﬁc manner
(Di et al., 2009). Glucocorticoid-induced endocannabinoid syn-
thesis and retrograde signaling speciﬁcally inhibited glutamate
release, while an enhanced GABA release has been associated
with the rapid stimulation of nitric oxide (NO) synthesis (Di
et al., 2009). Rapid glucocorticoid effects are dependent upon
G-protein and protein kinase activation as endocannabinoid syn-
thesis results from Gαs-induced production of cAMP and the
subsequent activation of PKA, whereas the activated Gβγ dimer
leads to activation of nNOS and NO synthesis. Whether such sig-
naling pathways can stimulate neurosteroidogenesis is currently
unknown, although the recent report that NMDA receptor acti-
vation stimulated neurosteroidogenesis via similar downstream
signaling pathways (i.e., MAPK, nNOS; Tokuda et al., 2011) sug-
gests the possibility of an analogous scenario (Figure 1). Further-
more, it is plausible that the impact of an NO-induced increase in
GABA release upon the inhibitory tone exerted on hypothalamic
magnocellular neurons could be further ampliﬁed by neurosteroid
potentiation of GABAAR function. Indeed, neurosteroids, such as
5α3α-THPROG, acting at presynaptic GABAARs, typically cause
an increase in synaptic transmission (Haage et al., 2002; Uchida
et al., 2002; Ruiz et al., 2010) due to the excitatory actions of
GABA on presynaptic terminals (Kullmann et al., 2005; Szabadics
et al., 2006; Trigo et al., 2008). Thus, following a stressful challenge,
locally produced neurosteroids may potentially modulate synaptic
transmission via actions at both pre- and postsynaptic GABAARs
(Figure 2C).
Intriguingly, in rodents both CRH and ACTH elevate the
brain and plasma levels of 5α3α-THPROG (Torres et al., 2001).
Similarly, in humans plasma levels of this neurosteroid were
elevated following CRH administration (Bernardi et al., 2000).
These observations are consistent with the proposal that neu-
rosteroids may be implicated in curtailing HPA axis activity.
Although it is unclear whether CRH directly stimulates neu-
rosteroid synthesis (see below on Neurosteroids and Ethanol),
a growing body of evidence indicates that CRH and its related
peptides (i.e., the urocortins) have extra-hypothalamic molecular
targets and, for example, may modulate synaptic transmission in
stress–sensitive regions such as the CeA, mPFC, and BST (Swan-
son et al., 1983; Bale and Vale, 2004; Gallagher et al., 2008).
Thus, it is conceivable that CRH-induced neurosteroidogenesis
may inﬂuence neurotransmission in a number of limbic and
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forebrain structures that are important for the processing of stres-
sor information. Moreover, the notion of a physiological role for
CRH-induced neurosteroidogenesis is further supported by the
observation that downstream G-protein coupled signaling path-
ways (e.g.,MAPK) associated with activation of CRH systems have
already been implicated in neurosteroidogenesis (Tokuda et al.,
2011; Figure 1).
Interestingly, the dendritic release of various neuropeptides
within the hypothalamus has been proposed as an important
mechanism in the functional reorganization of neuronal networks
(Ludwig and Leng, 2006) and may be involved in the coupling of
the hypothalamic neurohypophysial system and the HPA axis dur-
ing periods of stress (Engelmann et al., 2004). It is conceivable that
other neuropeptides such as oxytocin, AVP, and neuropeptide Y
(NPY), are similarly capable of stimulating or, indeed, inhibiting
neurosteroid synthesis. How these neuromodulators may inﬂu-
ence the coupling of neuronal networks thus warrants further
investigation.
Neuropeptides may not only inﬂuence the de novo synthesis of
3α-reduced steroids, but can additionally dynamically modulate
the neurosteroid sensitivity of GABAARs by changing the phos-
phorylation state of the receptor, or associated proteins. For exam-
ple, in magnocellular neurons of the SON, synaptic GABAARs,
while steroid-sensitive during pregnancy, become insensitive to
5α3α-THPROG24 h after parturition (Brussaard et al., 1997). This
dynamic shift in the pharmacology of the receptor, appeared to be
caused by an oxytocin-induced change in the relative activity of
endogenous phosphatases and PKC, acting to blunt the sensitivity
of GABAARs to the progesterone metabolite (Koksma et al., 2003).
Given that neuropeptide receptors share similarG-protein coupled
signaling pathways, CRH, NPY, and AVP also have the potential to
modulate GABAARneurosteroid sensitivity. The physiological sig-
niﬁcance of such a scenario has not been explored, although such
studies will be complex as the impact of phosphorylation upon
neurosteroid sensitivity of GABAARs is both kinase and neuron-
speciﬁc (Fancsik et al., 2000; Brussaard and Koksma, 2003; Harney
et al., 2003).
NEUROPEPTIDES, NEUROSTEROIDS, AND REWARD
PATHWAYS
There may be a reciprocal relationship between processing stress
and reward informationwithin the brain, as several commonbrain
structures are critically involved in their regulation. Thus, for
example, the extended amygdala [comprising the BST, the CeA,
and the posterior nucleus accumbens (NAc) shell], may mediate
many of the motivational effects of opposing processes (i.e., the
hedonic positive and negative emotional states that occur at dif-
ferent stages of drug taking), associated with drug dependence
(Koob and Le Moal, 2001). Interestingly, as noted above, the BST
inﬂuences HPA activity via projections to the PVN and appears to
be an important structure involved in the integration of stress-
related information originating in limbic and forebrain inputs
(Ulrich-Lai and Herman, 2009). In animal models, acute admin-
istration of drugs of abuse causes activation of the HPA axis, an
effect believed to facilitate drug reward by enhancing the activity
of brain motivational circuits, resulting in the acquisition of drug-
seeking behavior (reviewed in Koob, 2008). In contrast, the HPA
response to drugs of abuse becomes blunted following repeated
administration (Rasmussen et al., 2000; Semba et al., 2004), as high
levels of glucocorticoids may feedback to negatively regulate the
HPA axis (de Kloet et al., 2005; Koob, 2008). Additionally, elevated
glucocorticoid levels associated with repeated HPA axis activation
can “sensitize” extra-hypothalamic CRH systems (e.g., CeA) and
norepinephrine (NE) systems in the BLA, known to be involved
in behavioral responses to stressor exposure (Swanson and Sim-
mons, 1989; Imaki et al., 1991; Makino et al., 1994). As activation
of these extra-hypothalamic stress–sensitive targets characterizes
the withdrawal/negative affect stage of addiction, their dysregu-
lation may underpin at least some of the behavioral responses
associated with chronic drug treatment and withdrawal (Koob
and Kreek, 2007; Koob and Zorrilla, 2010). In agreement, sub-
stantial evidence indicates that extra-hypothalamic CRH systems
are activated during the development of dependence from ethanol
and other drugs of abuse (Koob, 2008). Furthermore, a number
of other anxiogenic (e.g., NE, dynorphin, orexin, AVP) and anx-
iolytic (NPY) neuropeptides have similarly been associated with
the transition to, and maintenance of, drug dependence (reviewed
in Koob, 2008).
As CRH administration induces an increase in the brain lev-
els of 5α3α-THPROG, endogenous neurosteroids may not only
be involved in regulating the activity of the HPA axis, but, given
the close association of the stress and reward systems, they may
additionally act as important modulators of the reward circuitry.
Indirect support for a close association between stress and reward
systems, comes from the clinical studies of drug addiction and
major depression. Thus, Enoch et al. (2010) have recently reported
an increased propensity particularly to cocaine addiction to seg-
regate with speciﬁc polymorphisms of the GABAAR α2 subunit
only when associated with a previous history of early life stress.
Further, deep brain stimulation of the NAc signiﬁcantly improved
clinical ratings of anhedonia, an inability to gain pleasure from
previously pleasurable activities, in patients suffering from forms
of depression resistant to pharmacological treatment (Schlaepfer
et al., 2008) thus, suggesting a dysfunction of the reward circuitry.
Interestingly, 5α-reductase is present in theNAc and the expression
of this enzyme is known to be sensitive to acute stress (i.e., swim
stress) in the mPFC (Sánchez et al., 2008) and to early chronic
psychosocial stress in both the mPFC and NAc (Bortolato et al.,
2011), suggesting that it may play a physiological role in both brain
regions (Bortolato et al., 2011). In support, 5α3α-THPROG inﬂu-
ences dopamine efﬂux in the NAc (Motzo et al., 1996; Rouge-Pont
et al., 2002). Furthermore, the systemic administration and intra-
accumbal infusion of 5α3α-THPROG in OVX rats signiﬁcantly
reduced the immobility time in the forced swim test, an animal
model of depression (Molina-Hernandez et al., 2005).
Collectively, these ﬁndings are consistent with the proposal
that the NAc may be an important site in mediating the putative
antidepressant actions of neurosteroids. Moreover, the stress–
protective actions of neurosteroids may contribute to such an
effect as the NAc innervates several important stress-related brain
structures including the BST, mPFC, BLA, in addition to several
hypothalamic nuclei (Ulrich-Lai and Herman, 2009).
A signiﬁcant body of work has investigated a possible relation-
ship between neurosteroids acting at the GABAAR and ethanol.
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Thus, in the ﬁnal section we will speciﬁcally focus on the putative
role of neurosteroids in the actions of alcohol.
ETHANOL AND NEUROSTEROIDS
Neurosteroids have been proposed as important mediators of
ethanol sensitivity and dysregulation of ethanol-induced neu-
rosteroidogenesis has been associated with an increased risk of
alcoholism (Morrow et al., 2006). Thus, a number of studies have
indicated that increased neurosteroidogenesis within the brain
contributes to some of the behavioral and electrophysiological
actions associated with ethanol administration (VanDoren et al.,
2000; Khisti et al., 2003; Sanna et al., 2004; Morrow et al., 2006;
Izumi et al., 2007; Boyd et al., 2010; Figure 1). For example, acute
ethanol treatment in CA1 pyramidal cells has been reported to
stimulate neurosteroid synthesis, resulting in an increase in the
peak amplitude and a prolongation of the decay time course
of mIPSCs recorded from these neurons (Sanna et al., 2004).
Moreover, acute ethanol (60mM) completely blocked LTP in
rat hippocampal slices, an effect attenuated by inhibition of 5α-
reductase by ﬁnasteride, or by the neurosteroid sequestering agent,
γ-cyclodextrin (Izumi et al., 2007; Tokuda et al., 2011). These
observations implicate neurosteroidogenesis in the suppression of
LTP by ethanol. Additionally, acute ethanol application increases
the frequency of mIPSCs recorded from CA1 pyramidal neurons.
However, in contrast to the ethanol effect upon mIPSC kinetics,
this action is not mimicked by a neurosteroid precursor (prog-
esterone) or by CP34 a TSPO “agonist,” suggesting this apparent
presynaptic effect of ethanol to be independent of neurosteroid
production (Sanna et al., 2004). A similar presynaptic effect of
ethanol occurs in the cerebellum (Carta et al., 2004) and amyg-
dala (Roberto et al., 2003; Nie et al., 2004). Interestingly, in the
latter this effect appears to be mediated by the activation of CRH
receptor 1 (CRH R1; Nie et al., 2004).
A role for CRH in ethanol actions is consistent with evi-
dence from animal models demonstrating the activation of extra-
hypothalamic CRH systems in the development of alcohol depen-
dence (Heilig and Koob, 2007; Koob, 2008), although whether
the effects of ethanol in the hippocampus involve CRH is not
known. As noted above, CRH also increases neurosteroid levels,
although the speciﬁc mechanisms underpinning such an action
are not fully elucidated (Torres et al., 2001). Interestingly, PKC,
and in particular the PKCε isoform, appears to be an impor-
tant mediator of CRH and ethanol-induced GABA release in
the CeA (Bajo et al., 2008). Additionally, this enzyme inﬂuences
the sensitivity of GABAARs to neurosteroids (Hodge et al., 1999;
Fancsik et al., 2000; Brussaard and Koksma, 2003; Harney et al.,
2003). Thus, a PKC-induced reduction in the neurosteroid sensi-
tivity of GABAARs (Brussaard and Koksma, 2003; Harney et al.,
2003 but see Fancsik et al., 2000) following ethanol administra-
tion has been suggested to contribute to an increase in alcohol
consumption as a consequence of the reduced neurosteroid sen-
sitivity (Morrow et al., 2006, also see below). However, the rela-
tionship between alcohol intake and neurosteroids is complex,
being both context and dose-related. Thus, for example, low doses
of 5α3α-THPROG increased while high doses reduced alcohol
intake in C57 mice (Ford et al., 2005). Equally, the progesterone
metabolite reduced alcohol intake in alcohol-dependent rodents,
while promoting ethanol consumption in non-dependent animals
(Morrow et al., 2001). Moreover, tolerance to the ethanol-induced
increase in neurosteroid levels developed in alcohol-dependent
animals (Khisti et al., 2005) and this adaptation may contribute to
the excessive alcohol consumption in such animals (reviewed in
Morrow et al., 2006). Conversely, heightened ethanol sensitivity,
associated with increased neurosteroid levels has been suggested
to prevent excessive alcohol consumption (Morrow et al., 2006).
Thus, restoration of ethanol sensitivity may have a therapeu-
tic advantage for the treatment of alcohol dependence, but this
remains to be tested in humans.
Interestingly, in addition to CRH, other anxiogenic neuropep-
tides have been consistently implicated in the development of
alcohol dependence (Heilig and Koob, 2007). Thus, the poten-
tial of these neuropeptide signaling systems to inﬂuence neu-
rosteroidogenesis during the development of alcohol and indeed,
other types of drug dependence, deserves further investigation. An
improved understanding of how neurosteroids and neuropeptide-
mediated signaling systems interact at different levels of the neu-
roaxis may provide insights into the pathology of not only alcohol
dependence, but also that of other drugs of abuse.
SUMMARY AND CONCLUSION
Since the seminal ﬁnding that mild stress elevates brain levels of
neurosteroids in rodents (Purdy et al., 1991), a growing body of
evidence has implicated GABAAR-active neurosteroids as impor-
tantmediators of the complex neuronal adaptations underpinning
the response to acute and chronic stress challenges. Moreover,
neurosteroids may represent important but overlooked molecular
players of the early programming of the stress response.
Converging data from the clinic and from animal models
indicates a close association between early life stress experiences
and the development of highly debilitating psychiatric conditions
including anxiety disorders, depression, and drug addiction. Of
relevance to neurosteroids, the impairment of brain signals medi-
ated by GABAARs is associated with early life adversities. However,
the contribution made by these potent, endogenous, GABAAR
modulators to the pathophysiology of these psychiatric conditions
is only now beginning to emerge. This realization is being comple-
mented by a better understanding of the role neurosteroids play
during early neuronal development and of their involvement in
the programming of the stress response. Collectively, this research
suggests that neurosteroids, or drugs that inﬂuence neurosteroid
synthesis,may offer a novel therapeutic approach to the treatment
of stress-related disturbances.
Many psychiatric disturbances have a recognized mixed genetic
and environmental basis such that a genetic predisposition does
not always imply an abnormal phenotype in the absence of signiﬁ-
cant environmental challenges, e.g., early life stress. As an example,
polymorphisms of theGABAARα2 subunit, a protein that is highly
expressed in stress-related neuronal circuits, confer susceptibility
to cocaine addiction, but only when these genetic abnormalities
are coincident with previous traumatic early life stress experiences
(Enoch et al., 2010). Although enzyme expression and function
is known to be sensitive to epigenetic regulation, the molecu-
lar mechanisms governing the neuron-selective expression and
function of the neurosteroid enzymatic machinery are still poorly
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understood. Signiﬁcant advances in this ﬁeld of research and
the development of neurosteroid-based therapeutic strategies will
require such mechanisms to be elucidated together with a better
understanding of their sensitivity to environmental inﬂuences.
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